Clinical Trial Update: A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study of Teclistamab in Japanese participants with relapsed or refractory multiple myeloma. The trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Hematologic Malignancies | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING